Biological Effects of Quercetin in COPD Phase II
Phase 2
30
about 1.7 years
40–80
1 site in PA
What this study is about
This trial is testing whether quercetin supplementation reduces inflammation and oxidative stress markers in people with chronic obstructive pulmonary disease (COPD). It involves a small number of participants receiving either a placebo, 1000 mg of quercetin daily, or 500 mg of quercetin daily for 638 days. The goal is to enroll approximately 30 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Quercetin 1000 mg
- 3.Take Quercetin 500 MG
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Immunological Agents
oral (Oral Tablet)
Primary: C-reactive protein (CRP), and surfactant protein (SP)-D in serum
Respiratory